How Spleen Size and Blood Counts Are Tracked During Myelofibrosis Treatment

The exam always starts the same way. He lies back, knees slightly bent, and the hematologist’s fingers press gently under his left ribs while he takes a slow breath in. “Four fingerbreadths,” she says, and writes it down next to the number from three months ago. That single measurement, repeated visit after visit, has become the quiet rhythm of his life with myelofibrosis.

For many people with this rare bone marrow condition, myelofibrosis spleen monitoring is the most tangible part of care. The spleen is the organ you can feel, the one that presses against your stomach at dinner and aches when you lean to the left. Blood counts are the part you cannot feel, yet they carry just as much weight in the room.

This explainer walks through what is actually measured, how the measurements are made, what the numbers tend to mean, and why your care team may seem more interested in the direction of travel than in any one result.

How does myelofibrosis affect the spleen?

Myelofibrosis is a chronic blood cancer in which scar tissue gradually replaces the spongy marrow inside the bones where blood cells are made. As the marrow stiffens, the body looks for other places to make blood. The spleen, an organ that filtered and recycled blood cells long before birth, takes up the job again. Doctors call this extramedullary hematopoiesis, which simply means blood production outside the marrow.

A healthy adult spleen is about the size of a fist, roughly 4 to 5 inches long, tucked under the left ribs where no one can feel it. In myelofibrosis it can swell to several times that size, sometimes reaching past the navel or across to the right side of the abdomen. The Cleveland Clinic notes that an enlarged spleen is usually a sign of an underlying process rather than a problem in its own right, and in this condition the process is the marrow’s failure to keep up.

The enlarged spleen in myelofibrosis does two unhelpful things. It produces abnormal cells inefficiently, and it traps normal ones. Platelets and red cells that pass through its widened channels can be held back or destroyed, a process called sequestration, so a bigger spleen often means lower counts. That is why the two tracks of monitoring, spleen size and blood counts, are read together rather than separately.

People feel the change in ordinary ways: fullness after a few mouthfuls, a dragging ache under the left ribs, weight loss without trying, breathlessness on stairs. The Mayo Clinic lists pain or fullness below the ribs on the left side among the most common early symptoms. Some people notice nothing until an examination finds it. The liver can enlarge for the same reason, and a routine visit usually checks both.

What happens at a myelofibrosis spleen monitoring visit

Most visits follow a predictable shape, which is reassuring once you know it. The conversation comes first. Your clinician asks about the symptoms that track disease activity: night sweats, itching, bone pain, early fullness, fatigue, unexplained fever and weight change. Many teams use a standardized symptom questionnaire, often ten items each scored from zero to ten, so that this month’s answers can be compared with last year’s rather than relying on memory.

Your weight is recorded. A steady fall in weight, with no change in diet, can reflect both a crowded abdomen and the metabolic cost of an overactive marrow and spleen.

Then comes the examination. You lie flat, and the clinician starts low on the right side of the abdomen and walks their fingers diagonally toward the left ribs while you breathe in. A spleen that has grown will slide down against the fingertips. The distance from the lowest edge of the rib cage to the tip of the spleen is measured in centimeters or fingerbreadths and written in the chart. The liver edge is checked the same way on the right.

A blood draw follows, usually a complete blood count with a manual review of the blood film, and often chemistry tests such as lactate dehydrogenase, uric acid, kidney and liver function, and iron studies if you have been receiving transfusions. Results may be back the same day or within a few days.

How often this happens depends on where you are in the illness. Someone newly started on a medicine may be seen every couple of weeks while counts settle. Someone stable on observation may come every three to six months. The interval is set by the treating team and will change as circumstances change; there is no single correct schedule that applies to everyone.

Spleen size measurement: palpation, ultrasound, MRI and CT compared

Each way of measuring the spleen answers a slightly different question, and each has a cost in time, precision or radiation. Understanding the trade-offs explains why your team may use one method in clinic and another for a formal assessment.

Palpation is fast, free of equipment and repeatable at every visit. Its weakness is precision. Body shape, bowel gas, muscle tension and the examiner’s technique all shift the number by a centimeter or two. A spleen that has not yet reached the rib margin is often unfeelable, so palpation says nothing about mild enlargement.

Ultrasound gives a length in centimeters along the spleen’s longest axis. The Cleveland Clinic describes ultrasound as a common first imaging test because it involves no radiation and can be repeated. Ultrasound length correlates reasonably with true size, but the spleen is an irregular three-dimensional organ, and length alone can underestimate a change in bulk.

MRI and CT calculate volume from a stack of cross-sectional images. This is the standard used in clinical trials, and it is the basis for the volume-based response definitions in the international consensus criteria published in the journal Blood. Volume is the most accurate measure but the most expensive in time, and CT adds ionizing radiation, so neither is used for routine month-to-month tracking.

The international criteria deliberately allow both approaches. A reduction of at least 35 percent in imaged volume is treated as roughly equivalent to a 50 percent reduction in palpable length when the baseline spleen extended 5 to 10 centimeters below the ribs, or to a spleen that becomes unfeelable when it started beyond 10 centimeters. In practice, many teams palpate at every visit and image at baseline, at a planned response assessment, and whenever the exam and the symptoms disagree.

What labs are abnormal with myelofibrosis?

The complete blood count in myelofibrosis rarely looks tidy, and the pattern shifts as the illness matures. MedlinePlus lists anemia as the most consistent finding, because scarred marrow makes red cells poorly and the spleen removes them too eagerly. Hemoglobin is therefore the value most people learn to read first.

White cells can go either way. Early in the disease they are often high, driven by the overactive marrow; later they may fall as fibrosis advances. Platelets follow a similar arc, frequently raised at diagnosis and drifting downward over years. Both extremes carry meaning, and both are recorded against previous values.

The blood film adds detail a machine cannot. Red cells shaped like teardrops, nucleated red cells that should still be inside the marrow, and immature white cells released early are the classic trio, sometimes summarized as a leukoerythroblastic picture. The percentage of blasts, the least mature white cells, is counted carefully because a rising blast count is one of the signals of progression discussed later.

Chemistry tests round out the picture. Lactate dehydrogenase, an enzyme released when cells turn over rapidly, is commonly elevated. Uric acid may be high for the same reason. Liver tests can drift if the liver enlarges. Ferritin and transferrin saturation are followed in anyone receiving repeated transfusions, because each unit of blood adds iron the body cannot excrete.

Genetic testing is usually done once at diagnosis rather than repeatedly. The Mayo Clinic notes that most people with myelofibrosis carry a change in one of three genes, JAK2, CALR or MPL, that switch on cell-growth signaling. Knowing which one is present helps with classification and risk assessment, and some centers repeat molecular testing if the disease appears to be changing character.

Reading your myelofibrosis blood test results over time

A single laboratory report is a photograph. Your care team is watching a film. The most useful habit you can build is to keep your own record of four numbers, hemoglobin, platelets, white cells and blast percentage, with the date beside each, so you can see the slope for yourself.

Hemoglobin tends to matter most for how you feel. A slow decline over a year is common and is weighed against symptoms and transfusion needs. A sharp drop over weeks prompts a search for another explanation such as bleeding, infection or a medicine effect.

Platelets set the safety boundaries for several treatments. Certain medicines are adjusted or paused when platelets fall below thresholds the prescriber has in mind, which is one reason counts are checked more often after any change in therapy. Your team, not the laboratory printout, decides what those thresholds are for you.

White cells are interpreted with the blast percentage. A rising total count with a stable, low blast fraction reads very differently from a modest count with blasts climbing toward double digits.

Transfusion frequency is itself a measurement. The international response criteria define transfusion dependence as needing red cells at a stated frequency over a stated period, and they count moving from dependence to independence as a response in its own right. If you receive transfusions, the interval between them is a number worth tracking.

Two practical cautions. Laboratories use slightly different reference ranges and machines, so compare results from the same laboratory when you can. And a value flagged as abnormal on a report is often expected in this condition; the question your clinician asks is not whether it is normal but whether it has changed.

Who is monitored closely and who is usually asked to wait

Not everyone with myelofibrosis is treated straight away, and observation is a decision rather than an absence of one. The Mayo Clinic describes a watch-and-wait approach for people who have no symptoms and stable counts, with treatment considered when symptoms, spleen size or blood values begin to cause problems.

People commonly asked to wait have a spleen that is not enlarged or only mildly so, hemoglobin in a range that does not limit daily life, no constitutional symptoms such as fevers or drenching sweats, a low blast percentage and a low score on a validated risk model. For them, the medicines currently available carry side effects without a clear benefit, and the monitoring schedule is typically every few months.

People monitored more intensively, and usually offered treatment, fall into several groups. Some have a spleen large enough to cause pain, early fullness or weight loss. Some have symptom scores that interfere with sleep, work or appetite. Some have falling hemoglobin or growing transfusion needs. Others have laboratory features that place them in a higher-risk category, where the discussion widens to include a stem cell transplant assessment.

Transplant deserves a sentence of its own. It is the only approach that aims to replace the diseased marrow, and it carries serious risks, so candidacy is judged on age, fitness, donor availability and disease risk rather than on spleen size alone. Referral for assessment is a separate step from deciding to proceed.

A pregnancy, a planned operation, or another serious illness can temporarily change how closely you are watched. What does not change is the principle: monitoring intensity follows risk, and the team adjusts it as the picture evolves.

How treatment response is judged: the consensus criteria in one table

Hematologists share a common language for describing whether a treatment is working, set out in the revised response criteria from the International Working Group for Myeloproliferative Neoplasms Research and Treatment and the European LeukemiaNet. The criteria exist mainly for clinical trials, but clinicians borrow them in everyday practice, and knowing them helps you understand phrases like “spleen response” or “anemia response” when they appear in your notes.

Two features of the criteria are worth highlighting before the table. First, any change has to be sustained for at least 12 weeks to count; a good week does not qualify. Second, a spleen response and an anemia response are assessed independently, so a medicine can shrink the spleen while hemoglobin stays flat, or the reverse.

What is measured	How it is measured	What counts as a response
Spleen volume	MRI or CT	At least 35 percent reduction from baseline
Spleen length (baseline 5–10 cm below ribs)	Palpation	At least 50 percent reduction in palpable length
Spleen length (baseline over 10 cm)	Palpation	Spleen becomes non-palpable
Anemia (not transfusion dependent)	Hemoglobin	Rise of at least 2 grams per deciliter
Anemia (transfusion dependent)	Transfusion record	Transfusion independence
Symptoms	Validated symptom score	At least 50 percent reduction in total score
Duration	All of the above	Sustained for at least 12 weeks

The categories above are drawn from the consensus report cited in the references. Real clinics work with softer edges. A spleen that shrinks by a quarter and stops hurting may be a perfectly good outcome for one person, even though it falls short of the formal definition. The criteria are a ruler, not a verdict, and the treating team decides what a meaningful result looks like for you.

What the first weeks and months of treatment usually look like

The most widely used medicines for spleen and symptom control belong to a class called JAK inhibitors. They block an overactive signaling pathway inside blood-forming cells, the same pathway that the common myelofibrosis gene changes switch on. Blocking it tends to reduce inflammatory signaling and slow the crowding of the spleen. The Mayo Clinic describes this class as a standard option for people with an enlarged spleen and troubling symptoms.

The early weeks often bring a paradox. Sweats, itching and appetite frequently improve within the first several weeks, sometimes before the spleen changes noticeably. At the same time, hemoglobin and platelets can dip, because the pathway being blocked also supports normal blood production. This is why blood counts are typically checked every two to four weeks at the start, with the schedule loosening as values stabilize; the exact cadence is set by the prescriber.

Spleen shrinkage is usually gradual. Clinic palpation may show the edge receding by a centimeter or two per visit. Formal imaging, when done, is commonly scheduled after the response window the consensus criteria require, so that any change has had time to prove it will last. Most trials have reported their primary spleen measurements around six months after starting, which is a reasonable expectation for when a formal judgement is made, not a promise of what it will show.

Other approaches have their own rhythms. Medicines aimed at anemia are judged over months by hemoglobin trend and transfusion interval. Radiation to the spleen, occasionally used when medicines are not suitable, is followed by frequent counts because it can lower them sharply. Surgical removal of the spleen is followed by a different monitoring pattern altogether, including vaccination planning and attention to platelet rebound.

None of this is a schedule to hold yourself to. It is a description of the terrain so that the frequent early blood draws feel purposeful rather than alarming.

Anemia in myelofibrosis: the number that often decides what happens next

If spleen size is the most visible measurement in myelofibrosis, hemoglobin is the most consequential. It shapes energy, breathlessness, concentration and the ability to walk up a hill. It appears in every major risk score. And it is the value most likely to change what your team recommends.

Anemia here has several causes acting at once. Scarred marrow produces fewer red cells. The enlarged spleen removes them faster. Chronic inflammation blunts the body’s response to its own red-cell hormone, erythropoietin. Some treatments lower hemoglobin as a side effect. Iron, folate or vitamin B12 shortfalls can add to the picture and are worth checking because they are easy to correct.

Monitoring anemia therefore involves more than the hemoglobin figure. Your team looks at red cell size and shape, reticulocytes (young red cells that show whether the marrow is trying), iron studies, and the transfusion diary if you have one. A pattern of transfusions creeping closer together is one of the clearest signals that the balance is shifting.

Transfusion itself is a treatment that needs monitoring. Each unit delivers iron that the body has no route to remove, and over dozens of units this can accumulate in the liver and heart. Ferritin is followed for this reason, and iron-lowering therapy may be discussed once a threshold the team has in mind is passed.

The consensus criteria treat anemia response as its own category, separate from spleen response, precisely because the two do not move together reliably. A medicine that halves the spleen may leave hemoglobin unchanged; another may lift hemoglobin while the spleen stays put. The Johns Hopkins overview of myelofibrosis frames anemia management as a central strand of care in its own right. Which strand takes priority at any given moment is a judgement for you and your treating team together.

Myelofibrosis progression signs: what a changing picture looks like

People with myelofibrosis often ask what progression would look like, and the honest answer is that it rarely announces itself with one event. It shows up as a cluster of shifts across the same measurements you have been tracking all along.

On the physical side, a spleen that grows despite treatment, or begins to hurt sharply rather than ache, is a signal. Constitutional symptoms returning after a quiet period, such as night sweats that soak the sheets, unexplained fevers, or weight falling steadily, are others. Bone pain, particularly in the long bones, can reflect a marrow under increasing strain.

On the laboratory side, the changes clinicians watch most closely are a rising percentage of blasts on the blood film, a falling hemoglobin that no longer stabilizes between transfusions, platelets drifting downward, and a white cell count moving sharply in either direction. Lactate dehydrogenase climbing is a nonspecific but consistent companion. A repeat bone marrow biopsy may be arranged to see whether fibrosis has deepened or the blast fraction has increased there.

The most serious form of progression is transformation to acute myeloid leukemia, an aggressive cancer of immature white cells. By convention this is defined by blasts reaching 20 percent or more in the blood or marrow, a figure set in international classification systems and reflected in the response criteria cited in this article. The Mayo Clinic lists this transformation among the complications of myelofibrosis. Transformation occurs in a minority of people, and the risk scores discussed next exist partly to estimate how likely it is.

Distinguishing progression from a medicine effect, an infection or a nutritional problem is the everyday work of monitoring. A new low count on its own proves nothing; the same low count, with a bigger spleen and more blasts, tells a story. Bring the trend, not just the latest result, to any conversation about whether things are changing.

What the risk scores measure and why your score can change

Hematologists use scoring systems to sort myelofibrosis into risk groups, and understanding them takes some of the mystery out of the phrase “intermediate-2” when it appears in a letter. The most widely known dynamic model, DIPSS, was developed by an international working group and published in the journal Blood.

DIPSS awards points for five features: age over 65, hemoglobin below 10 grams per deciliter, a white cell count above 25 billion per liter, blasts of 1 percent or more in the blood, and the presence of constitutional symptoms such as weight loss, fever or night sweats. The word dynamic matters. Unlike scores calculated once at diagnosis, DIPSS is designed to be recalculated at any point, so it reflects where you are now rather than where you started.

Newer models add platelet count, transfusion need, marrow fibrosis grade, chromosome findings and specific gene mutations. They are more precise but need more information, and they are used mainly when a major decision such as transplant referral is on the table.

Notice what these scores share with routine monitoring. Hemoglobin, white cells, blasts and symptoms are the same values that come back with every blood draw and every clinic conversation. Monitoring is, in effect, continuous risk assessment; a shift in one number nudges the score, and enough shifts can move you between categories.

Two cautions from the evidence. Scores describe groups, not individuals, and the ranges they generate are wide. And they were built from people with primary myelofibrosis; those whose disease evolved from polycythemia vera or essential thrombocythemia may be assessed with adapted tools. Your team will tell you which model they are using and what your current category means for the options in front of you.

What are the most common causes of death in myelofibrosis, and what is monitoring trying to catch?

This is the question people type into a search engine at two in the morning, so it deserves a straight answer. Myelofibrosis shortens life for many people, though the range is very wide, from a few years to several decades, depending on risk category and age. The Mayo Clinic and MedlinePlus both describe it as a progressive condition whose course varies considerably between individuals.

Published cohorts consistently identify a handful of pathways. Transformation to acute leukemia, described in the previous section, accounts for a substantial share. Infections are frequent, because white cells may be low or poorly functioning and because some treatments dampen immunity further. Bleeding can follow low platelets or the widened, fragile vessels around an enlarged spleen and liver. Clotting events, including strokes and heart attacks, remain a feature of all myeloproliferative conditions. Heart failure can develop from years of anemia and iron overload. Portal hypertension, raised pressure in the veins draining the gut through the liver, is a less common but serious complication of massive splenic blood flow.

Each of these has a monitoring counterpart. Blast percentage and marrow biopsy watch for transformation. White cell counts, fever history and vaccination records address infection. Platelets and bleeding symptoms cover hemorrhage. Cardiovascular risk factors are tracked as they would be in anyone. Ferritin watches iron. Liver tests, ultrasound and clinical signs such as fluid in the abdomen watch for portal pressure.

The point of laying this out is not to frighten but to explain why the visit feels so thorough. Every question about fever, every glance at the platelet count, every check of the liver edge is aimed at one of these pathways. Monitoring cannot prevent every outcome, and no one should read this section as a forecast for their own situation; the person who can interpret your numbers against these risks is the clinician who knows your history.

What people often get wrong about myelofibrosis spleen monitoring

Some misunderstandings surface so often in clinic that they are worth correcting directly.

Myth: a bigger spleen always means the disease is worse. Spleen size is one marker among several. Some people have enormous spleens and stable counts for years; others have modest spleens and rapidly changing blood values. The risk scores discussed earlier do not include spleen size at all, which tells you how the evidence weighs it.

Myth: a shrinking spleen means the disease is being reversed. Medicines that reduce spleen size mostly do so by quieting inflammatory signaling and the crowding of the spleen. The marrow scarring beneath is generally not undone by these medicines, and the response criteria treat spleen response and marrow response as separate categories for exactly this reason. Feeling better and having a smaller spleen are real, worthwhile benefits; they are not the same thing as disease reversal.

Myth: one abnormal blood count is an emergency. Almost every count in myelofibrosis is abnormal by laboratory reference ranges. Clinicians react to change, context and symptoms, not to the red flag beside a number.

Myth: imaging is always better than a hand on the abdomen. Imaging is more precise, but it is not needed at every visit, and repeated CT scans expose you to radiation without adding much to a stable picture. Palpation at each visit plus imaging at chosen points is the pattern the evidence supports.

Myth: if you feel well, nothing is changing. Constitutional symptoms are a powerful signal, but blast percentages and hemoglobin can drift silently. Feeling well is good news, and it is still worth keeping the appointment.

Myth: massage, supplements or particular foods can shrink the spleen. No mainstream evidence supports this. Any product promising to reduce spleen size is making a claim it cannot back, and firm abdominal pressure on a very large spleen is inadvisable because the organ can be injured.

Questions to ask your care team about spleen and blood count monitoring

A good appointment is a two-way exchange, and knowing what to ask often matters more than knowing the answers in advance. The questions below are starting points; choose the ones that fit your situation and write down the replies.

• How far below my ribs does my spleen currently extend, and how does that compare with my first measurement?
• Are you following my spleen by examination alone, or is imaging planned, and if so which type and when?
• Which of my blood values are you most focused on right now, and what direction of change would prompt a conversation about altering treatment?
• What is my current risk category, which scoring system did you use, and has it changed since diagnosis?
• How often do you expect to see me and check blood over the next year, and what would make that more or less frequent?
• If I am receiving transfusions, how many have I had, and are you monitoring my iron levels?
• Which symptoms should I report between visits, and which can wait until the next appointment?
• Am I a candidate for transplant assessment, and if not now, what would change that?
• Are there clinical trials relevant to my situation, and how would monitoring differ if I joined one?
• Who do I contact, and how, if something changes on a weekend or overnight?

Bring a written log of your own numbers and symptoms. A simple table with dates, hemoglobin, platelets, white cells, blast percentage, transfusion dates and a one-line note on how you felt is more useful to your clinician than any recollection. If a family member or friend can attend with you, ask them to take notes so you can concentrate on the conversation. And if an answer uses a term you do not recognize, ask for it in plain words; that request is always reasonable.

When to call your doctor

Most changes in myelofibrosis unfold over months and are picked up at scheduled visits. A smaller number need attention within hours or days. Do not wait for the next appointment if you notice any of the following.

Seek urgent care the same day, or emergency care if severe, for: sudden, severe pain under the left ribs or in the left shoulder, which can indicate bleeding into or around the spleen or a loss of its blood supply; a fever, particularly with chills or feeling generally unwell, since a low or poorly functioning white cell count can turn an ordinary infection serious quickly; vomiting blood, passing black or tarry stools, or bleeding that does not stop with pressure; sudden breathlessness, chest pain, or a swollen and painful calf, which may signal a clot; sudden weakness, facial drooping, confusion or difficulty speaking; and any fall or blow to the abdomen, because an enlarged spleen is vulnerable to rupture.

Contact your care team within a day or two for: new or worsening night sweats, fevers without an obvious cause, or bone pain; rapidly increasing fullness or a visibly larger abdomen; fatigue or breathlessness that has stepped up noticeably over a week or two, which may reflect falling hemoglobin; unexplained bruising, bleeding gums or small red spots on the skin, which can accompany low platelets; and weight loss you have not been trying to achieve.

Keep your team’s contact numbers, including the out-of-hours route, somewhere you can find them without searching. Many people find it helps to carry a card or phone note stating that they have myelofibrosis and an enlarged spleen, so that emergency staff know immediately why the abdomen must be handled gently and why counts need checking early. None of the signs above confirms a particular problem; each is a reason for the people who know your history to take a look promptly.

Frequently asked questions

How does myelofibrosis affect the spleen?

Scar tissue in the bone marrow forces blood production into the spleen, which enlarges as it takes on the work. The swollen organ also traps and destroys normal platelets and red cells, so a larger spleen often goes with lower blood counts. People notice fullness after small meals, a left-sided ache and weight loss. Liver enlargement can occur for the same reason.

What labs are abnormal with myelofibrosis?

Anemia is the most consistent finding. White cells and platelets may be high early and low later. The blood film typically shows teardrop-shaped red cells, nucleated red cells and immature white cells, sometimes with blasts. Lactate dehydrogenase and uric acid are often raised. Most people carry a JAK2, CALR or MPL gene change, usually tested once at diagnosis.

What are the signs that myelofibrosis is progressing?

Progression usually appears as a cluster of changes rather than one event: a spleen growing despite treatment, returning night sweats or fevers, steady weight loss, bone pain, falling hemoglobin with more frequent transfusions, dropping platelets, and a rising blast percentage. Blasts reaching 20 percent define transformation to acute leukemia. Your team distinguishes these from medicine effects or infection by looking at trends.

What are the most common causes of death in patients with myelofibrosis?

Published cohorts identify transformation to acute leukemia, infection, bleeding, clotting events such as stroke or heart attack, heart failure related to long-term anemia and iron overload, and complications of portal hypertension. Each has a monitoring counterpart, from blast counts to platelet checks and ferritin. Individual outcomes vary widely, and only the clinician who knows your history can interpret your risk.

How is spleen size measurement by ultrasound different from a physical exam?

Palpation estimates how far the spleen extends below the left ribs in centimeters and is quick enough to repeat at every visit, but examiner technique and body shape affect the result. Ultrasound measures the spleen’s length directly without radiation. MRI or CT calculate volume and are the standard in trials. Many teams palpate routinely and image at planned points.

How often are blood counts checked during myelofibrosis treatment?

The interval depends on where you are in the illness. After starting or changing a medicine, counts are commonly checked every two to four weeks until values settle, because some treatments lower hemoglobin and platelets early. People on stable observation may have blood drawn every three to six months. The schedule is set and adjusted by your treating team.

What does a spleen response mean in myelofibrosis?

In the international consensus criteria, a spleen response is a reduction of at least 35 percent in volume on MRI or CT, or a 50 percent reduction in palpable length when the spleen started 5 to 10 centimeters below the ribs, or a spleen that becomes unfeelable when it started beyond 10 centimeters. The change must last at least 12 weeks.

Can an enlarged spleen in myelofibrosis shrink on its own?

Meaningful spontaneous shrinkage is uncommon, because the marrow scarring that drives spleen growth is progressive. Size can fluctuate slightly with hydration, bowel contents and examiner technique, which is one reason single measurements are not over-interpreted. Sustained reduction is generally associated with treatment. No food, supplement or massage has evidence for reducing spleen size, and firm pressure on a large spleen is unsafe.

Why does my hemoglobin drop after starting a JAK inhibitor?

JAK inhibitors block a signaling pathway that is overactive in myelofibrosis but also supports normal red cell and platelet production. An early dip in hemoglobin and platelets is therefore common in the first weeks, which is why counts are checked frequently at the start. Whether the dip is acceptable, and how to respond, is a judgement for the prescribing clinician.

What is the DIPSS score and does it change over time?

DIPSS is a dynamic risk model that scores age over 65, hemoglobin below 10 grams per deciliter, white cells above 25 billion per liter, blasts of 1 percent or more, and constitutional symptoms. Because it uses values that are measured at every visit, it can be recalculated at any time and your category can move. Newer models add platelets, transfusion need and genetic findings.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.